Bagsværd, Denmark, 23 April 2014 - At Novo Nordisk's Annual General Meeting on 20 March 2014, it was decided to reduce the company's B share capital from DKK 442,512,800 to DKK 422,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 100,000,000 B shares of DKK 0.20 each.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Frank Daniel Mersebach | +45 3079 0604 | fdni@novonordisk.com |
Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Jannick Lindegaard (US) | +1 609 235 8567 | jlis@novonordisk.com |
Company announcement No 25 / 2014